Biology subjects

Kang, J.

Publications and source records attributed to Kang, J..

At least 19 recordsLinked to original sources

bioRxiv2026

Oxytocin modulates behavioral economic and dopaminergic measures of motivation to seek intravenous oxycodone in rats

The opioid epidemic persists despite available pharmacotherapies for opioid use disorder (OUD), motivating interest in treatments targeting the motivational and neurochemical substrates of opioid seeking. Peripherally administered oxytocin (OT) attenuates drug seeking and consumption across substances and modulates the mesolimbic dopamine system, yet its effects on opioid seeking and its underlying neurobiology remain poorly characterized. Here we investigated the effects of OT on behavioral and dopaminergic measures of opioid reinforcement using in vivo fiber photometry with the dopamine sensor, GRABDA2m, in the nucleus accumbens (NA) core of male and female rats. Daily OT (15 IU/kg, IP) administered 30 min prior to operant sessions increased demand elasticity for intravenous oxycodone self-administration in males but not females. Acute OT (15 and 45 IU/kg, IP) increased GRABDA2m dopamine signal in the NA core in females, and potentiated oxycodone-evoked dopamine release in both sexes. In a high-effort task, NA core dopamine increased prior to lever presses, and acute OT (15 IU/kg, IP) produced sex-divergent effects on phasic NA core dopamine release during lever pressing, increasing peak signal and area under the curve measures in males. Support vector machine classifiers determined that features of dopamine transients (e.g., mean peak, standard deviation of the amplitude, peak-valley range) before an active lever press distinguished between treatment and sex. Thus, the ability of chronic oxytocin to reduce the motivation to self-administer oxycodone in male rats is independent of oxycodone-induced NA dopamine release but rather may involve dopamine transmission during lever pressing under high effort conditions.

neuroscience↗

bioRxiv2026

A mast cell receptor is associated with fibrosis and itch in systemic sclerosis

Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by symmetric fibrosis of the skin and multiple internal organs. The mechanisms that trigger early fibrotic changes remain unclear. Mast cells are known to infiltrate human SSc lesional skin in early disease stages, yet the role of mast cells in initiating fibrosis and pruritus in SSc remains debated, in part due to unclear pathways of mast cell activation. Here, we show that mast cells, via the receptor Mrgprb2, contribute to fibrosis in the bleomycin (BLM)-induced skin fibrosis mouse model. Mast cells accumulate in the skin of BLM-treated wild-type (WT) but not Mrgprb2-knockout (Mrgprb2-/-) mice. Mrgprb2-/- mice show attenuated disease severity, with reduced collagen deposition and lower expression of matrix metalloproteinases and inflammatory markers associated with fibrosis. BLM treatment also increases pruritus in WT mice in the early stages of the model; an effect reduced in Mrgprb2-/- mice. This is the first report of itch in this model of skin fibrosis, further linking it to clinical SSc, where pruritus is an early and prevalent symptom affecting nearly half of patients. In a parallel human cohort, lesional SSc skin harbors significantly more mast cells than paired non-lesional skin from the same patients, demonstrating that mast cell accumulation is specific to affected tissue. Lesional mast cell counts also track with skin disease severity, correlating with modified Rodnan skin score and patient-reported skin tightness. Together, these findings implicate Mrgprb2-mediated mast cell activity in both fibrosis and pruritus in SSc, highlighting mast cells as a candidate therapeutic target in this understudied disease process.

immunology↗

bioRxiv2026

Cancer stem cell transcriptomic signatures reveal patient-to-patient heterogeneity emphasizing the need for patient-specific ovarian cancer targets

Background/Objectives: In high-grade serous ovarian cancer (HGSOC), the abilities of tumor cells to resist cytotoxic treatment and relapse are largely driven by ovarian cancer stem cells (CSCs). CSCs are a population of cells within a tumor that maintain stem-like qualities and have the capacity to produce metastasis and drive drug resistance. Based on the complexity of CSC signaling and emerging evidence of differential isoform usage in development, we hypothesize that CSCs possess a patient-specific, heterogeneous landscape which exploits isoform diversity to sustain stemness, metastasis and drug resistance. Methods: RNA-seq was generated from 3 patient-derived HGSOC (PD-HGSOC) to investigate stemness and differentiation status comparing standard culture and CSCs. The data was analyzed at both gene- and isoform-levels to identify patient-specific CSC features and define mechanisms of cancer-related stemness and plasticity. Results: CSCs exhibited higher stemness characteristics and identified differentially expressed gene sets across PD-HGSOCs. We noted that each patient had a distinct subset of genes regulating stemness phenotypes which suggested multiple mechanisms of CSC development and maintenance. Additionally, a large proportion of gene-level expression changes were driven by the differential expression of a single predominant isoform. Importantly, our isoform-level analysis enabled the identification of differential isoform usage that would not be detected with gene level expression analysis. Conclusions: CSC phenotypes such as chemoresistance, metastasis and self-renewal are conserved across patients, but arise from largely patient-specific gene and isoform programs. This CSC heterogeneity is reflective of the heterogeneity seen in patients and should be further evaluated in deriving precision-medicine approaches for HGSOC.

cancer biology↗

bioRxiv2026

Hopeaphenol targets histidine kinase signaling across kingdoms to suppress bacterial virulence and potentiate plant immunity

Small molecules can control plant disease either by disarming the pathogen or by priming host immunity, but single compounds that do both are rare and mechanistically unexplained. Here we show that hopeaphenol (HP), a resveratrol tetramer from stilbene producing plants, acts on histidine kinase (HK) signaling on both sides of the Arabidopsis-Pseudomonas interaction. In Pseudomonas syringae pv. tomato DC3000, HP represses the type III secretion regulon and motility genes, restricts surface motility independently of effector delivery, and binds a defined subset of virulence-associated sensor kinases while reducing their autophosphorylation; comparable engagement occurs in Pectobacterium atrosepticum. Binding and inhibition depend on the tetrameric scaffold rather than the resveratrol monomer. In the host, HP binds the CHASE domains of the cytokinin receptors AHK2, AHK3 and AHK4 and elicits an immune-associated, rather than canonical cytokinin, transcriptional output. HP-dependent potentiation of PTI and ETI responses and early restriction of bacterial growth require AHK3 and AHK4. HP thus coordinates opposing outputs from divergent HK systems across kingdoms.

plant biology↗

bioRxiv2026

SCG: Spatially Co-Expressed Gene Identification through Spatially Varying Networks

Spatial transcriptomics has enabled the advancement of gene expression analysis, yet spatial co-expression remains understudied. We introduce spatial covariance regression (SCR), a scalable Bayesian factor-model-based framework for estimation of spatially-resolved gene co-expression networks across tissue domains. These networks provide the spatial map of gene-gene correlations and enable the identification of spatially co-expressed genes (SCGs), which serve as potential prognostic biomarkers and therapeutic targets.

genomics↗

bioRxiv2026

Enhancing Mycobacterial Clearance via Heterologous BCG Prime Boost Strategy Using Recombinant Mycobacterium smegmatis

Bacille Calmette-Guerin (BCG) remains the only licensed tuberculosis (TB) vaccine, yet its protective efficacy against adult pulmonary TB is limited. To overcome this, we evaluated a novel recombinant Mycobacterium smegmatis (rMs) booster vaccine expressing Ag85B and ESAT-6 via the pMyong2 vector, combined with oat-derived {beta}-glucan adjuvant, to enhance BCG-primed immunity. BALB/c mice were primed with BCG and boosted twice with homologous BCG or varying doses of rMs with or without {beta}-glucan. Five weeks post-booster, mice were challenged intraperitoneally with M. tuberculosis H37Ra. Systemic bacterial clearance in liver tissue, cell-mediated immunity IFN-{gamma}, IL-17a, and antibody responses IgG, IgG2c, IgA were evaluated 3 weeks post-challenge. All rMs booster groups (rMs, high-dose rMs H, low-dose with {beta}-glucan, rMs {beta}) achieved complete systemic clearance of H37Ra with no detectable CFUs (colony forming unit), significantly outperforming mock-vaccinated and repeated BCG groups (**p < 0.01). Repeated BCG revaccination showed higher bacterial loads than single BCG (***p < 0.001), confirming no booster effect. Low-dose rMs with {beta}-glucan maintained 100% survival and total bacterial elimination despite a 50% dose reduction. Immune markers did not strictly correlate with clearance. Homologous BCG revaccination provides no additive protection, whereas pMyong2-based rMs confers robust systemic bacterial clearance. Adjuvanting with {beta}-glucan enables dose reduction while preserving maximum efficacy, establishing rMs as a promising heterologous TB booster candidate.

immunology↗

bioRxiv2026

ABCB1-Mediated Drug Efflux Drives Resistance to VpreB1-Targeted Antibody-Drug Conjugates in B-cell Lymphoblastic Leukemia

Although B-cell acute lymphoblastic leukemia (B-ALL) is highly responsive to antigen-directed immunotherapies, treatment resistance remains a major barrier to achieving durable responses in patients. We recently developed a novel VpreB1 (CD179a)-directed antibody-drug conjugate with calicheamicin (VpreB1-ADC) that exploits the restricted expression of VpreB1 within the surrogate light chain in early B cells, including B-ALL. In the present work, we investigated mechanisms of resistance to the VpreB1-ADC. Mechanisms of resistance were evaluated using a TCF3::HLF B-ALL model, assessing target engagement parameters including VpreB1 surface expression and antibody internalization. The role of the multidrug resistance transporter ABCB1 (P-glycoprotein) was evaluated via pharmacologic inhibition, using tariquidar and zosuquidar, and enforced overexpression across multiple B-ALL cell lines. Sensitivity to alternative non-ABCB1 substrate payloads exatecan and PNU-159682 was also assessed. Resistant TCF3::HLF cells retained VpreB1 expression and efficient antibody internalization. Instead, resistance was driven by elevated ABCB1 expression and activity. ABCB1 inhibition with tariquidar or zosuquidar restored VpreB1-ADC sensitivity. Conversely, enforced ABCB1 overexpression conferred ADC resistance, which was reversed by ABCB1 inhibition. Cells with high ABCB1 activity remained fully sensitive to alternative payloads, including exatecan and PNU-159682, which are not ABCB1 substrates. ABCB1-mediated drug efflux drives intrinsic resistance to calicheamicin-conjugated ADCs in B-ALL. Combining ADCs with ABCB1 inhibitors or selecting payloads non-susceptible to ABCB1 efflux offer viable strategies to overcome resistance and optimize future ADC therapies.

cancer biology↗

bioRxiv2026

GDTR: Layer-wise Settling Depth Reveals Biological Grammar in Genomic Foundation Models

Genomic foundation models capture sequence regularities, yet existing interpretability tools rarely ask where in the layer stack a biological grammar becomes stable. We introduce GDTR (Genomic Deep-Thinking Ratio), a training-free residual-stream lens that assigns each nucleotide token a settling depth c(t): the first layer at which its representation stabilises against the post-final-norm reference. On Evo 2 7B, splice donor and acceptor sites settle approximately two layers earlier than intronic contexts, enhancer-like cCREs show a smaller but measurable shift, and a chr22 calibration transfers to held-out chr17. Perturbing canonical splice donors shows that the signal is bidirectional: disrupting the central GT motif deepens settling, whereas shuffling the flanking grammar makes the preserved motif settle earlier. Differential GDTR further reveals consequence-associated peak-disruption depths across ClinVar variants, with synonymous substitutions peaking deepest but with broad class overlap. GDTR therefore provides a layer-wise interpretability axis for genomic foundation models, complementary to existing prediction and variant-scoring tools.

bioinformatics↗

bioRxiv2026

Spatial Metabolomics by Desthiobiotin Ligase (DESTNI) in Live Cells

Proximity labeling has transformed spatial proteomics by enabling compartment-resolved mapping of protein environments in living cells, yet its extension to small-molecule metabolites has not been demonstrated, probably due to limitations in labeling chemistry and labeled metabolites identification. Here, we introduce DESTNI, an engineered desthiobiotin (DTB) ligase derived from TurboID through directed evolution, and establish a platform for spatially resolved profiling of amine-containing metabolites. A directed evolution strategy based on a yeast display system yielded DESTNI with efficient DTB-dependent reactivity, enabling robust and compartment-specific proximity labeling across diverse subcellular environments. To identify the DTB-modified amino metabolome, we developed an integrated analytical framework combining DTB-modified amino metabolite standards, in vitro DESTNI profiling, and in silico MS/MS prediction, enabling systematic annotation of DTB-modified amino metabolites. To extend this chemistry to metabolites, we combined synthetic DTB-conjugated metabolite reference standards, in vitro DESTNI-reactive metabolite discovery, and machine-learning prediction of DTB-derivatized metabolites and oligopeptides. Organelle-targeted DESTNI recovered reproducible compartment-enriched amino metabolite signatures, including mitochondrial matrix-enriched glycine, 5-aminolevulinic acid, ornithine and spermidine adducts, as well as nuclear-enriched {gamma}-aminobutyric acid and 5-aminovaleric acid adducts. Together, this work establishes DESTNI as a proximity labeling platform that bridges spatial proteomics and metabolomics and provides a general strategy for mapping subcellular biochemical environments in living cells.

biochemistry↗

bioRxiv2026

Single-Molecule Imaging Reveals Differential Stability of Alpha-Synuclein Aggregates

-Synuclein (-syn) aggregation is central to Parkinsons disease (PD), yet measurements in biofluids are confounded by the coexistence of monomeric and aggregated species. Using Syn-IMAGR, a single-molecule imaging platform with sub-femtomolar sensitivity, we show that purified -syn aggregates undergo dilution-induced disassembly, revealing a concentration-dependent equilibrium. Applied to postmortem brain lysates, Syn-IMAGR distinguishes physiological -syn multimers, which are dimmer and readily dissociate upon dilution, from PD-associated aggregates, which remain detectable and exhibit greater structural resistance to disruption. These results indicate that -syn assemblies occupy distinct stability regimes, with PD-associated aggregates representing a more persistent and less dilution-sensitive structural state. Syn-IMAGR thus provides a quantitative framework for resolving -syn species and for probing their concentration-dependent equilibrium.

neuroscience↗

bioRxiv2026

From hotspot dependence to distributed robustness in resistance-aware lead optimization

Drug resistance remains a recurrent failure mode in targeted anticancer and antiviral therapy, and resistance evidence often enters only after compound selection. ResistAgent is an evidence-constrained framework that converts mutational liabilities into design-time objectives through site- and combo-aware resistance mapping, deterministic mechanism diagnosis and robust counter-design. In EGFR-Erlotinib and HIV-RT-Rilpivirine, the framework separated residue-level liabilities from observed HIV combination liabilities and linked prioritized mutations to anchor loss, pocket rearrangement, electrostatic shifts and contact redistribution. Same-budget paired searches showed that robust objectives changed lower-tail mutant-panel behavior and interaction-dependence profiles while prioritizing robustness over average-affinity behavior. Under predefined liability panels, robust-objective trajectories shifted support away from mutable hotspot contacts toward more distributed interaction networks. Supplementary physical summaries and ranking-first benchmarks support the validation envelope of this resistance-aware design strategy.

bioinformatics↗

bioRxiv2026

Water oxidation-driven histidine dioxidation enables probe-free proximity labeling

Photocatalytic proximity labeling (photo-PL) has emerged as a powerful tool for spatial proteomics in subcellular compartments. However, many photo-PL toolboxes rely on singlet oxygen (1O2) to generate highly unstable endoperoxide intermediates that must be trapped immediately by high concentrations of exogenous probes. This constraint can bias spatial proteome coverage, particularly in dynamic and heterogeneous compartments such as endosomes and exosomes, where probe accessibility is intrinsically nonuniform. Here, we develop IDM, an organic photocatalyst that generates hydroxyl (*OH) and superoxide (O *-) radicals via water oxidation instead of 1O , enabling a synergistic dual-radical mechanism for probe-free proximal protein mapping in live cells (PF-Map). The resulting radicals dioxidize proximal histidine residues into a persistent dioxidized state (His-2O) that is thermodynamically stabilized as lactam tautomers, which remain electrophilic and chemically addressable after cell lysis. By decoupling histidine oxidation from live{square}cell probe capture, PF{square}Map can minimize spatial bias arising from heterogeneous probe distribution. Applying PF{square}Map to intracellular vesicle trafficking, we find that both PF{square}Map and a probe{square}dependent workflow (PD{square}Map) robustly identify exosome markers, whereas PF{square}Map additionally reveals a hidden vesicle trafficking-related subproteome that PD-Map underestimated. Together, we establish a minimally biased photocatalytic strategy for spatial protein mapping in complex biological systems. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/731337v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@13da43dorg.highwire.dtl.DTLVardef@1e9cb7corg.highwire.dtl.DTLVardef@2e7557org.highwire.dtl.DTLVardef@19e16c_HPS_FORMAT_FIGEXP M_FIG C_FIG

biochemistry↗

bioRxiv2026

4 Phenylbutyrate Plus Gene augmentation: A dual therapy To Rescue of SLC6A1 Variant Associated Developmental And Epileptic Encephalopathy

BackgroundPathogenic variants in SLC6A1, which encodes the {gamma}-aminobutyric acid (GABA) transporter GAT-1, cause developmental and epileptic encephalopathies (DEEs) through reduced GABA uptake, impaired transporter trafficking, and functional haploinsufficiency. 4-Phenylbutyrate (PBA) is a clinically available small molecule with chemical-chaperone and histone-deacetylase-inhibitor activities that can rescue misfolded GABAergic proteins, but variant-level rescue data are needed to guide precision treatment. MethodsWe report a newly identified de novo SLC6A1 missense variant, p.Ala305Val (A305V), in a patient with myoclonic-atonic epilepsy and a developmental and epileptic encephalopathy phenotype. A305V was compared with the residue-matched comparator p.Ala305Thr (A305T). Variant effects were evaluated by (i) protein-structure prediction across nine stability-prediction algorithms using the cryo-EM-derived human GAT-1 template (PDB 7Y7W); (ii) 3H-GABA uptake assays in HEK293T cells and in human iPSC-derived astrocytes and cortical neurons; (iii) live-cell confocal microscopy of ER colocalization; (iv) pharmacologic rescue with PBA, TUDCA and salubrinal (v) and GAT-1 cDNA gene-augmentation, alone and in combination with PBA. ResultsAI-based stability predictors uniformly indicated destabilization of GAT-1(A305V) and GAT-1(A305T). A305V reduced 3H-GABA uptake across HEK293T, astrocyte, and neurons. The mutant transporter accumulated within the endoplasmic reticulum (ER), with ER colocalization rising from approximately 30% in wildtype to [~]80% in A305V; PBA reduced ER retention to approximately [~]40% and restored total GAT-1 fluorescence toward wildtype levels. Pharmacochaperones (PBA, TUDCA) restored GABA uptake for the mutant transporters. Wildtype GAT-1 gene augmentation improved mutant GAT-1 uptake and combined PBA-plus-augmentation produced rescue greater than either intervention alone in the available dose-response ranges. ConclusionsSLC6A1 A305V is a trafficking-impaired, loss-of-function GAT-1 variant whose dysfunction is tractable to two convergent therapeutic axes: pharmacologic correction of folding and trafficking, and augmentation of functional transporter dose. These findings support a two-pronged precision-medicine framework for SLC6A1-related DEEs in which PBA increased the transporter function augmented by increased gene therapy. Significance of the studyThis work links the patient-derived SLC6A1 A305V variant to a defined molecular mechanism--GAT-1 destabilization, ER retention, and reduced GABA uptake--and demonstrates that the deficit is reversible by two independent interventions that converge at the same downstream endpoint of functional surface transporter. Because PBA is already clinically deployable and GAT-1 cDNA augmentation models a future viral or non-viral gene therapy, the combined-rescue logic provides a falsifiable path for precision medicine in SLC6A1-related DEEs: chemical chaperoning corrects the folding bottleneck while transporter augmentation increases the pool available for rescue.

neuroscience↗

bioRxiv2026

Early-Life Exposure to Warming Enhances Sea Urchin Heatwave Tolerance but Fails under Extreme Stress

The exposure to environmental stressors early in life can shape organisms to express more tolerant phenotypes to the same conditions during adulthood, a process called developmental plasticity. However, this acquired acclimation ability might depend on the intensity of the stimulus perceived later in life. Here, we took advantage of a purple sea urchin Paracentrotus lividus population developed at abnormally high sea temperature in the proximity of a power plant to test the limits of their developmentally acquired plasticity to increased water temperature. We simulated two marine heatwaves, a category I (moderate) and IV (extreme), and exposed the power plant population as well as a naive population developed in natural sea conditions. We measured their respiration rate and molecular responses to these two heatwaves. Regardless of the population of origin, sea urchins exposed to heatwaves showed higher oxygen consumption, indicating an increase in metabolic rates. At the molecular level, the biggest difference between the two populations was found following the moderate heatwave. Compared to the developmentally acclimated sea urchins, the naive population expressed genes coding for proteins with stress response, chromatin remodeling and RNA splicing functions, while suppressing immune response, revealing that developmental exposures can aid in priming the responses of adults to moderate temperature increases. However, a stronger heatwave leveled the differences between the two populations, with sea urchins from both locations expressing genes involved in proteostasis and detoxification. Nevertheless, regardless of the simulated marine heatwave intensity, sea urchins from the naive population always showed enrichment of the spliceosome pathway compared to power plant urchins, which activated immune response genes instead, reflecting fundamentally different thermal stress-coping strategies shaped by their developmental environments. Overall, our results demonstrate the critical yet context-dependent role of developmental plasticity in shaping the resilience of marine ectotherms to climate change.

evolutionary biology↗

bioRxiv2026

4-Phenylbutyrate Rescue in GABRA1 Variants Associated with Developmental Epileptic Encephalopathies: from Cell and Mouse Models to Human

Disease variants in GABR genes encoding {gamma}-Aminobutyric acid type A receptor (GABAAR) subunits are major causes of developmental and epileptic encephalopathies (DEEs). There is no effective treatment for these DEEs although the GABAAR is a major target for antiseizure drugs. We previously identified the therapeutic effect of 4-phenyl-butyrate (PBA) in Gabrg2+/Q390X knockin DEE mice and now test the effect of the drug in GABRA1 variants that encode the 1 subunit. We used a multidisciplinary approach including in silico structural modeling, flow cytometry, patch clamp recordings and bio-chemistry in conjunction with differential tagging of the wild-type and the mutant alleles to evaluate the effect of PBA on rescue of GABAAR subunit expression, surface trafficking, and function in vitro in heterologous HEK293T cell model and in vivo in Gabra1+/A322D mice. We found that both total and cell surface 1 expression was reduced when the variant 1 protein was present; suggesting reduced functional receptor on the cell membrane and synapse. Patch clamp recordings identified 1 variants reduced GABA-evoked current amplitude. In silico prediction indicated reduced protein stability for GABRA1 variants indicated by negative {Delta}{Delta}G values. PBA increased both total and surface expression of wildtype 1 and 1 variants; and improved expression of both wildtype and variant 1 alleles when these were co-expressed. Importantly, PBA also increased the GABAAR expression in the thalamus of the Gabra1+/A322D mice. This study indicates that PBA is a promising treatment option for DEEs associated with GABRA1 mutations. Our previous work has demonstrated that PBA improves proteostasis by enhancing expression of the wildtype allele, repairing the mutant allele, and reducing endoplasmic reticulum stress. Therefore, it can mitigate seizures and improve neurobehavioral phenotypes at behavioral levels. Based on this and our previous work on GABRG2 and SLC6A1 mutations, we propose that PBA holds promise as a common medicine for multiple genetic neurologic disorders that share the proteostasis pathology with a broad clinical application in DEEs.

neuroscience↗

bioRxiv2026

Hierarchical Immune Suppressive Functions of Regulatory T Cells Built on Mechanical Force

Regulatory T (Treg) cells maintain immune tolerance via contact-dependent inhibition and soluble mediators. While canonical suppressive mechanisms are well characterized, their hierarchical spatiotemporal organization remains unclear. We previously showed Foxp3 represses ER Ca2+ channel RyR2, reducing cytoplasmic Ca2+ to inactivate m-Calpain (Calpain-2) and stabilize high-affinity LFA-1-mediated Treg-dendritic cell (DC) adhesion--an early step blocking DC antigen presentation. Using m-Calpain as a molecular switch, we generated mechanically deficient Tregs (TregFD) with constitutively active m-Calpain that abrogated high-force Treg-DC adhesion. TregFD retained a near-wild-type transcriptome (differential expression limited to adhesion pathways), yet failed to suppress autoimmunity or DC-driven T cell proliferation. Stable adhesion was required for localized TGF-{beta}/IL-10 delivery to DCs. Single-cell RNA sequencing of rescued Scurfy mouse lymphoid tissues revealed organ-specific division of labor: non-mechanical modules support homeostasis/tissue repair, while mechanical modules dominate epithelial barrier/antigen presentation suppression. Combined TregFD and RyR2-deficient Tconv transfer restored wild-type Treg activity, demonstrating module synergism. These findings establish a mechanical force-centered, two-tiered hierarchical model of Treg suppression, providing a framework for targeting Treg mechanics in autoimmunity and inflammation.

immunology↗

bioRxiv2026

Expansion Revealing of Pathology Resolves Nanostructures Associated with Inflammatory Phenotypes in COVID-19 Decedent Human Brain Tissue

Expansion revealing (ExR) elucidates cellular organization by separating proteins within dense nanostructures by 20x linear expansion, but requires fixation procedures incompatible with human pathology specimens. Here, we report ExR of pathology (ExRPath), which attains [~]20 nm resolution and decrowding of such tissues, through iterative 20x expansion, adapted to human brain pathology specimens. We also report a single-shot 15x expansion protocol for such tissues (15ExMPath), achieved through one-shot 15x expansion. Applying ExRPath and 15ExMPath to COVID-19-decedent brain tissue reveals periodic amyloid nanoclusters that co-localize with SARS-CoV-2 in a rare minority of patient specimens, pointing to a potential neuroinflammatory phenotype associated with COVID-19, and highlighting the power of high-throughput nanoimaging, empowered by expansion microscopy, for discovering potential novel disease mechanisms.

neuroscience↗

bioRxiv2026

Label free multimodal optical imaging of metabolic heterogeneity in aging by integrating SRS, MPF, FLIM, and SHG

Cellular metabolism is governed by the coordinated organization of macromolecules, including lipids and proteins, together with redox-active cofactors such as NADH and FAD. However, resolving these biochemical features quantitatively and spatially at subcellular resolution remains challenging because no single imaging modality can capture molecular composition, redox state, and tissue architecture simultaneously without labeling. Here, we present MANIFEST (Multimodal Analysis of Nonlinear Imaging for Functional Endogenous Spatial correlaTion), a label-free imaging platform that integrates stimulated Raman scattering (SRS), second harmonic generation (SHG), multiphoton fluorescence (MPF), and fluorescence lifetime imaging microscopy (FLIM) with their spatial correlation. MANIFEST combines chemical imaging of lipids with autofluorescence- and lifetime-based quantification of NADH and FAD metabolism, enabling spatially resolved analysis of metabolic heterogeneity at organelle and tissue-compartment levels. We apply this framework to four distinct aging or disease models: amyloid-beta-treated tri-cultured brain cells, high-fat diet mouse liver, human non-ischemic cardiomyopathy tissue, and aging mouse retina. Across these systems, MANIFEST reveals disease-associated lipid remodeling, redox imbalance, disrupted metabolic zonation, collagen reorganization, and layer-specific metabolic changes. By integrating complementary nonlinear optical modalities into a single label-free platform, MANIFEST provides an extensible, proof-of-concept platform for high-resolution metabolic phenotyping in complex biological systems and offers new opportunities for studying disease mechanisms, aging biology, and metabolism-driven tissue pathology.

bioengineering↗